Description
SENTINEL™ SPECTRUM™ is available in four strengths in color-coded packages for oral administration to dogs and puppies according to their weight. Each chewable flavored tablet is formulated to provide a minimum of 0.23 mg/pound (0.5 mg/kg) of milbemycin oxime. Each chewable tablet is formulated to provide a minimum of 22.8 mg (0.5 mg/kg) of praziquantel. The chewable tablets contain two active ingredients, milbemycin oxime and praziquantel, and are designed for easy administration to dogs, even those that swallow whole. The tablets may be broken into pieces and fed to dogs that normally swallow treats whole. Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes after medication to ensure that no part of the dose is lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.

Dosage Schedule

<table>
<thead>
<tr>
<th>Body Weight</th>
<th>Milbemycin per chewable</th>
<th>Praziquantel per chewable</th>
<th>Number of chewables</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 to 8 lbs.</td>
<td>2.3 mg</td>
<td>22.8 mg</td>
<td>One</td>
</tr>
<tr>
<td>8.1 to 25 lbs.</td>
<td>5.75 mg</td>
<td>115 mg</td>
<td>One</td>
</tr>
<tr>
<td>25.1 to 50 lbs.</td>
<td>11.5 mg</td>
<td>230 mg</td>
<td>One</td>
</tr>
<tr>
<td>50.1 to 100 lbs.</td>
<td>23.0 mg</td>
<td>460 mg</td>
<td>One</td>
</tr>
<tr>
<td>Over 100 lbs.</td>
<td>Administer the appropriate combination of chewables</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

To ensure adequate absorption, always administer SENTINEL SPECTRUM to dogs immediately after or in conjunction with a normal meal.

SENTINEL SPECTRUM may be offered to the dog by hand or added to a small amount of dog food. The chewables should be administered in a manner that encourages the dog to chew; rather than to swallow without chewing. Chewables may be broken into pieces and fed to dogs that normally swallow treats whole. Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes after medication to ensure that no part of the dose is lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.

Heartworm Prevention
SENTINEL SPECTRUM should be administered orally, once every month, at the minimum dosage of 0.23 mg/pound (0.5 mg/kg) of milbemycin oxime and 22.8 mg (0.5 mg/kg) of praziquantel. For heartworm prevention, give once monthly for at least 6 months after exposure to mosquitoes (see EFFECTIVENESS).

Sentinel Spectrum should not be administered to pregnant or nursing females or to puppies that are less than 2 pounds of body weight. Sentinel Spectrum is not effective against immature microfilariae that may be present in the heart of infected dogs. Sentinel Spectrum should not be administered to puppies that are less than 6 weeks of age. Sentinel Spectrum is not recommended for use in breeding dogs. Sentinel Spectrum should not be administered within 24 hours of any other compound that is being administered orally by the dog, except as directed by the veterinarian. Sentinel Spectrum should be administered to dogs in accordance with the label directions on the tablet package. Sentinel Spectrum should be administered once a month and the tablets should be stored in a cool, dry place.

Precautions
Sentinel Spectrum should be administered to dogs already on a heartworm preventative program. Sentinel Spectrum should be administered to dogs already on a heartworm preventative program and the tablets should be stored in a cool, dry place. Sentinel Spectrum should be administered once a month and the tablets should be stored in a cool, dry place.

Adverse Reactions
The following adverse reactions have been reported in dogs after administration of milbemycin oxime, lufenuron, or praziquantel: vomiting, depression/lethargy, pruritus, urticaria, diarrhea, anorexia, skin congestion, ataxia, convulsions, and salivation. In addition, a mild transient decrease in activity, tremors, and salivation was seen within 24 hours of treatment. Splayed hind limbs were observed once in two dogs in the 5X maximum exposure dose of Sentinel Spectrum group. No adverse reactions were observed in any of the dogs treated with doses less than 12.5 mg/kg. Lufenuron: A rising-dose safety study conducted in rough-coated Collies resulted in ataxia, ptosis, and periodic recurrency in one of four dogs administered milbemycin oxime at 12.5 mg/kg (5X the maximum exposure dose of Sentinel Spectrum). Prior to dosing, a 25.1 to 50 lb. dog on day 6 of the study had undergone a dosing regimen consisting of 2.5 mg/kg of milbemycin oxime on day 3, followed by 5.0 mg/kg on day 14, and 10.0 mg/kg on day 32. No adverse reactions were observed in any of the Collins treated with doses less than 12.5 mg/kg. Lufenuron: In a ten-month study, doses of lufenuron up to 2X the maximum exposure dose of Sentinel Spectrum (10 mg/kg) caused no overt toxicity. A single dose of 200 mg/kg had no marked effect on adult dogs, but caused decreased activity and reduced appetite for at least 8 weeks after treatment. Although Sentinel Spectrum tablets were evaluated with concurrent administration of flea adulticides containing carbaryl, permethrin, cypermethrin, and pyriproxyfen. Toxicity resulting from these combinations. Lufenuron tablets did not cause cholinesterase inhibition nor did they enhance cholinesterase inhibition caused by exposure to organophosphates. Two laboratory and two well-controlled field studies were conducted to evaluate reproductive safety of lufenuron tablets in breeding dogs. In one of the laboratory studies, in which lufenuron was administered to Beagle dogs as three divided doses, equivalent to 17.5X the maximum exposure dose of Sentinel Spectrum (10 mg/kg), the ratio of gravid females to females mated was 9.8/100 in the control group and 6/97 in the lufenuron-treated group. The mean number of pups per litter was 7.5 animals lower in the lufenuron versus control groups and the mean birth weights of pups from treated bitches in this study was lower than control groups. These pups grew at a similar rate to the control pups. The incidence of clinical changes, including diarrhea, lethargy, and salivation, were higher in the lufenuron-treated pup group than in the control group. At the lower dose levels, these changes were transient and decreased by the end of lactation.

Side Effects
Results from two additional reproductive safety studies, one laboratory and two field studies, evaluating treatment of the same breed of dogs, demonstrated no adverse effects for pre- or postnatal development in the offspring of dams treated with Sentinel Spectrum. Sentinel Spectrum should not be administered within 24 hours of any other compound that is being administered orally by the dog, except as directed by the veterinarian. Sentinel Spectrum should be administered to dogs in accordance with the label directions on the tablet package. Sentinel Spectrum should be administered once a month and the tablets should be stored in a cool, dry place.

Storage Information
Store in a dry place at controlled room temperature, between 59° and 77°F (15°-25°C).

How Supplied
SENTINEL SPECTRUM is available in four strengths, formulated according to the weight of the dog. Each strength is available in color-coded packages of six or twelve chewable tablets each. Manufactured for: Vetvac AI, Inc.
P.O. Box 162509. Pl. Worth, TX 76161
NADA #141-333, Approved by FDA
© 2015 Vetvac Corporation. All Rights Reserved.
SBE, SENTINEL, and spectrum are registered trademarks of Virbac Corporation.
01/16
32003-01

46162927